8-K: DarioHealth Corp. Amends Preferred Stock Terms, Extends Conversion Period

DarioHealth Corp. has amended the terms of its Series C, C-1, and C-2 Preferred Stock, extending the mandatory conversion period and adjusting dividend terms.

Summary

• DarioHealth Corp. filed amended certificates of designation for its Series C, C-1, and C-2 Preferred Stock on May 20, 2025.
• The amendments extend the mandatory conversion period for these preferred stocks from 15 to 24 months from the original issue date.
• The company will issue a dividend equal to 15% of the number of shares of Common Stock issuable upon conversion of the Series C Preferred Stock, Series C-1 Preferred Stock and/or Series C-2 Preferred Stock then held by such holder for each full quarter anniversary of holding following the filing of the Series C Certificates of Designation with the Secretary of State of the State of Delaware.
• No additional securities were issued or sold as a result of these amendments.

Sentiment

Score: 6

Explanation: The document describes a routine corporate action. The extension of the conversion period is neither particularly positive nor negative, but provides the company with more flexibility.

Positives

• Extending the conversion period may provide the company with more flexibility in managing its capital structure.
• The dividend structure could be attractive to investors holding the preferred stock.

Risks

• The conversion of preferred stock could dilute existing common shareholders.
• The company's ability to issue common stock upon conversion is subject to beneficial ownership and primary market limitations.

Future Outlook

The company's future actions will involve managing the conversion of the preferred stock and ensuring compliance with ownership limitations.

Industry Context

Companies often adjust the terms of their preferred stock to manage their capital structure and attract investors.

Comparison to Industry Standards

• Comparable companies in the healthcare technology sector, such as Teladoc Health or Livongo (prior to its acquisition by Teladoc), also utilize preferred stock and convertible securities as part of their financing strategies.
• The specific terms, such as conversion periods and dividend rates, are tailored to the company's specific needs and market conditions.
• The 15% dividend for each full quarter is relatively high, which may be attractive to investors but could also represent a significant cash outflow for the company if many shares are not converted.

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the preferred stock.
• Preferred stockholders will benefit from the extended conversion period and the dividend structure.

Next Steps

• The company will need to monitor the conversion of the preferred stock and manage the issuance of common stock.
• The company will need to ensure compliance with beneficial ownership and primary market limitations during conversion.

Key Dates

Keywords

preferred stock, conversion, dividends, DarioHealth, amendment, Series C, Series C-1, Series C-2, common stock